BRVE Insider Trading Activity and SEC Form 4 Filings
BRVE insider trading summary
Over the past 12 months, insiders at Braveheart Bio, Inc. (BRVE) reported 26 open-market purchases worth $482.7M by 18 insiders and no sales on SEC Form 4. Net insider buying was $482.7M.
Latest BRVE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 7, 2026 | Travis Murdoch | CEO and President | Buy | $1.5M (83,333 @ $18.00) |
| Aug 7, 2026 | Michele A. Anderson | Chief Development Officer | Buy | $20K (1,111 @ $18.00) |
| Aug 7, 2026 | David I Malek | Director | Buy | $75K (4,166 @ $18.00) |
| Aug 7, 2026 | Christopher Viehbacher | Director | Buy | $1.5M (83,333 @ $18.00) |
| Aug 7, 2026 | James Paul Rickey | Chief Financial Officer | Buy | $500K (27,777 @ $18.00) |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | Buy | $34.6M (1,920,000 @ $18.00) |
| Aug 7, 2026 | Forbion Ventures Fund VII Cooperatief U.A. | Insider | Buy | $34.6M (1,920,000 @ $18.00) |
| Aug 7, 2026 | Forbion Ventures VII Management B.V. | Insider | Buy | $34.6M (1,920,000 @ $18.00) |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | Insider | Buy | $30.2M (1,680,000 @ $18.00) |
| Aug 7, 2026 | David Charles Lubner | Director | Buy | $1000K (55,555 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.